Synopsis A recent clinical study demonstrates that increased sympathetic activity can be a biomarker for predicting the chances of bone deterioration in patients with pheochromocytoma (PCC). This week's ' MED FACT ' discusses a clinical trial from Bone, “ Higher sympathetic activity as a risk factor for skeletal deterioration in pheochromocytoma ”. 2018.
Authors : Beom-Jun Kim, Mi Kyung Kwak, Jae Seung Kim et al. Key Takeaways Higher sympathetic activity increases skeletal deterioration in patients with pheochromocytoma (PCC) leading to osteoporosis . Objective Study Type Participants To study the role of sympathetic activity in bone deterioration in patients with PCC Cross Section Study (Randomized and Open-Label) 295 What…
